Sterically Stabilized Carrier For Aerosol Therapeutics, Compositions And Methods For Treating The Respiratory Tract Of A Mammal

Abstract

This invention comprises a sterically stabilized liposome carrier encapsulating a selected drug for the aerosol delivery of the drug effectual in the treatment of a mammal, a composition containing the sterically stabilized liposome carrier and a drug effective for the treatment a mammal as an aerosol and a method of treatment using the composition. The composition provides effective treatment for the longer of a period of time at least twice as long as the drug alone or up to at least one week.

1 - 25 . (canceled) 
     
     
         26 . A method for treating a mammal with a drug effective for treatment of asthma and inflammation, said method comprising
 a) treating the mammal with the drug by forming an aerosol of a composition consisting of a sterically stabilized liposome carrier encapsulating an effective amount of the drug effective for treatment of a mammal, the sterically stabilized liposome carrier consisting essentially of phosphatidylcholine, phosphatidylglycerol, and poly(ethylene glycol)distearoylphosphatidyl diethanolamine (PEG-DSPE) the composition being of a particulate size up to about 0.2 to about 5.0 microns and effective to result in deposit of the drug in the airways down to the alveoli and alveolar tight junction and having a gel-liquid transition temperature from about −20° C. to about 44° C. and providing an effective life for the drug in a mammal equal to at least twice the life of a single dose of the drug or at least one week and,   b) allowing the mammal to inhale an effective amount of the aerosol at a selected time interval.   
     
     
         27 . The method of  claim 26  wherein the drug is a corticosteroid, an anti-inflammatory drug, a peptide, a protease inhibitor, a bronchodilator, a leukotriene inhibitor, an antihistamine, or an anti-tuberculosis drug. 
     
     
         28 . The method of  claim 26  wherein the drug is selected from the group consisting of: budesonide (BUD), triamcinolone (TRI), monophosphoryl lipid A (MPL), apo1 lipoprotein A-1 mimetic (D-4F), serine lung protease inhibitor (SLPI) and combinations thereof. 
     
     
         29 . The method of  claim 26  wherein the sterically stabilized liposome carrier further comprises cholesterol. 
     
     
         30 . The method of  claim 29  wherein the sterically stabilized liposome carrier contains from about 1 to about 33 mole percent cholesterol. 
     
     
         31 . The method of  claim 26  wherein the sterically stabilized liposome carrier contains up to about 98.5 mole percent phosphatidylcholine, up to about 98.5 mole percent phosphatidylglycerol, from about 0.5 to about 10 mole percent PEG-DSPE and from about 1 to about 33 mole percent of the drug. 
     
     
         32 . The method of  claim 29  wherein the sterically stabilized liposome carrier contains from about 60 to about 90 mole percent phosphatidylcholine, from about 10 to about 40 mole percent phosphatidylglycerol, from about 1 to about 5 mole percent [poly(ethylene glycol)]PEG-DSPE, from about 0.1 to about 20 mole percent cholesterol and from about 1 to about 33 mole percent of the selected drug. 
     
     
         33 . The method of  claim 26  wherein the selected time interval for the effective life of the drug in the respiratory tract of the mammal is at least two days and up to two weeks.